A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)

Fibrodysplasia Ossificans Progressiva Clinical Trial

Official title:

A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02322255
• Other study ID #: PVO-1A-001
• Status: Completed
• Start date: December 18, 2014
• Est. completion date: April 9, 2020

Study information

• Verified date: June 2020
• Source: Ipsen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by painful, recurrent episodes of soft tissue swelling (flare-ups) that result in abnormal bone formation in muscles, tendons, and ligaments. Flare-ups begin early in life and may occur spontaneously or after soft tissue trauma, vaccinations, or influenza infections. Recurrent flare-ups progressively restrict movement by locking joints leading to cumulative loss of function and disability. This 3-year, non-interventional, two-part, natural history study is designed to gain insight into total body HO, FOP disease progression, the impact of FOP on subjects' physical functioning, and clinical features and biomarkers that may be useful in the diagnosis and monitoring of disease progression. This natural history study will also provide important information to inform the design of subsequent interventional trials.

Description:

This is a multi-center, natural history, non-interventional, longitudinal study in subjects with classic FOP. A thorough baseline examination will be performed to determine the current status of disease in each subject. In Part A, two imaging modalities assessed total body HO at baseline, and the optimal method (low-dose whole body CT scan [excluding head]) will be employed in Part B for the balance of the study. Progression will be assessed at annual in-clinic visits (ie, at Months 12, 24, and 36) at which time the procedures conducted at the baseline visit will be repeated. In addition, site personnel will telephone subjects midway between the annual visits (ie, at Months 6, 18, and 30).

During the 36-month follow-up period, at least one new flare-up (with a maximum of one per year) will be carefully studied. An in-clinic visit will be performed within 14 days following the subject's identification of his/her flare-up. Additional visits at Day 42 and Day 84 (after the initial flare-up clinic visit) will be performed. An additional future visit may be scheduled after Day 84 at the discretion of the Principal Investigator (PI) for prolonged flare-ups. However, subjects with an eligible flare-up may elect to participate in an ongoing Clementia interventional study rather than continue in this natural history study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: April 9, 2020
• Est. primary completion date: April 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 65 Years

Eligibility

Inclusion Criteria:

• Subjects clinically diagnosed with classical FOP with documented R206H mutation or believed to carry the R206H mutation

Exclusion Criteria:

• Participation in an interventional clinical research study within the 4 weeks prior to enrollment

Related Conditions & MeSH terms

• Fibrodysplasia Ossificans Progressiva

Locations

Country	Name	City	State
Argentina	Hospital Italiano de Buenos Aires, Department of Pediatrics	Buenos Aires
Australia	Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)	Woolloongabba	Queensland
France	Hôpital Necker-Enfants Malades, Department of Genetics	Paris
Italy	Gaslini Institute, Unit of Rare Diseases, Department of Pediatrics	Genoa
United Kingdom	The Royal National Orthopaedic Hospital, Brockley Hill	Stanmore	Middlesex
United States	University of Pennsylvania, Center for FOP & Related Bone Disorders	Philadelphia	Pennsylvania
United States	University of California San Francisco, Division of Endocrinology and Metabolism	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Clementia Pharmaceuticals Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  France,  Italy,  United Kingdom, 

References & Publications (3)

Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993 Feb;75(2):215-9. — View Citation

Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64(1):76-83. — View Citation

Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, Kaplan FS, Wang P. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013 Dec;57(2):386-91. doi: 10.1016/j.bone.2013.09.002. Epub 2013 Sep 17. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the total body burden of heterotopic ossification as assessed by the optimal imaging modality (low-dose whole body CT [excluding head]).		Month 36
Secondary	Change from baseline in physical function as assessed by range of motion.		Month 12, Month 24, and Month 36
Secondary	Change from baseline in patient-reported use of assistive devices and adaptations.		Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36
Secondary	Change from baseline in a disease-specific patient-reported outcome measure (FOP-Physical Function Questionnaire [FOP-PFQ]).		Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36
Secondary	Change from baseline in a patient-reported measure of physical and mental health (PROMIS Global Health Scale).		Month 6, Month 12, Month 18, Month 24, Month 30, and Month 36
Secondary	Change from baseline in biomarkers.		Month 12, Month 24, and Month 36
Secondary	Flare-up progression as assessed by the change from baseline in heterotopic ossification at the flare-up site.		Flare-up initiation, Flare-up Days 42 and 84
Secondary	Flare-up progression as assessed by the change from baseline in pain and swelling at the flare-up site.		Flare-up initiation, Flare-up Days 42 and 84
Secondary	Flare-up progression as assessed by the change from baseline biomarkers.		Flare-up initiation, Flare-up Days 42 and 84
Secondary	Flare-up progression as assessed by the change from baseline in physical function as assessed by range of motion.		Flare-up initiation, Flare-up Days 42 and 84
Secondary	Flare-up progression as assessed by the change from baseline in a disease-specific patient-reported outcome measure (FOP-Physical Function Questionnaire [FOP-PFQ]).		Flare-up initiation, Flare-up Days 42 and 84
Secondary	Flare-up progression as assessed by the change from baseline in a patient-reported outcome measure of physical and mental health (PROMIS Global Health Scale).		Flare-up initiation, Flare-up Days 42 and 84

External Links

•   Click here for more information about this study: A Natural History, Non-Intervention Study in Subjects with Fibrodysplasia Ossificans Progressiva (FOP)
•   website for the International FOP Association